Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Epigenetic silencing including histone modifications and DNA methylation is an important tumorigenic mechanism. However, its role in cancer immunopathology and immunotherapy is poorly understood. Using human ovarian cancers as our model, here we show that enhancer of zeste homologue 2 (EZH2)-mediated histone H3 lysine 27 trimethylation (H3K27me3) and DNA methyltransferase 1 (DNMT1)-mediated DNA methylation repress the tumour production of T helper 1 (TH1)-type chemokines CXCL9 and CXCL10, and subsequently determine effector T-cell trafficking to the tumour microenvironment. Treatment with epigenetic modulators removes the repression and increases effector T-cell tumour infiltration, slows down tumour progression, and improves the therapeutic efficacy of programmed death-ligand 1 (PD-L1; also known as B7-H1) checkpoint blockade and adoptive T-cell transfusion in tumour-bearing mice. Moreover, tumour EZH2 and DNMT1 are negatively associated with tumour-infiltrating CD8(+) T cells and patient outcome. Thus, epigenetic silencing of TH1-type chemokines is a novel immune-evasion mechanism of tumours. Selective epigenetic reprogramming alters the T-cell landscape in cancer and may enhance the clinical efficacy of cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“epigenetic reprogramming with shRNAs targeting DNA methyltransferase 1 (DNMT1) or pan-DNMT blockers like decitabine and guadecitabine has been shown to resemble EZH2 inhibition in its capacity to promote CXCL9 and CXCL10 secretion in various models of breast, lung, and ovarian carcinoma”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Peng et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several studies have demonstrated that mutations in genes involved in the SWI-SNF chromatin remodeling complex may sensitize human tumors to ICIs and that treatment with an epigenetic modulator can potentiate the ICI-mediated antitumor response through increased production of chemokines responsible for recruiting CD8 + T cells (104-107).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [107]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The mTOR pathway has long been recognized to play a pivotal role in integrating signals at the cellular level and promote autoimmunity and carcinogenesis18,19.”
From Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation (2019) · cites this paper as [19]
Experimental — accuracy not yet measuredIn the citing paper
“and TH1 cytokines”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Peng et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Self-citationIntratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker
Heagerty, P. J., Lumley, T., & Pepe, M. S. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00337.x · Cited by 2,854
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Cited by
Items 201–300 of 1,000
Hao, X., Li, C., Zhang, Y., Wang, H., Chen, G., Wang, M., & Wang, Q. (2018) · Advanced Materials · doi:10.1002/adma.201804437 · Cited by 145
Kumar, H., Gupta, N., Jain, R., Madhunapantula, S. V., Babu, C. S., Kesharwani, S. S., Dey, S., & Jain, V. K. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.02.005 · Cited by 153
“TAAs increase the expression of CD8 + T lymphocytes in tumors by chemokines and interleukins [212,213].”
BackgroundZhang, M., Liu, Z. Z., Aoshima, K., Cai, W. L., Sun, H., Xu, T., Zhang, Y., An, Y., Chen, J. F.-Y., Chan, L.-H., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abf5473 · Cited by 155
“12 of 16 CXCL9 and CXCL10, critical for T helper 1 cell trafficking to ovarian tumors (55).”
BackgroundLocalization, tissue biology and T cell state — implications for cancer immunotherapy
Schenkel, J. M., & Pauken, K. E. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00884-8 · Cited by 151
“However, tumours can turn off chemokine expression directly through multiple mechanisms, including epigenetic silencing 76,84,85 (Fig.”
BackgroundDu, W., Hua, F., Li, X., Zhang, J., Li, S., Wang, W., Zhou, J., Wang, W., Liao, P., Yan, Y., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1571 · Cited by 147
“Additionally, tumors may evade tumor immunity by impairing effector T-cell trafficking into the tumor microenvironment via altered β -catenin signaling (13), epigenetic mechanisms (14, 15), and other biological pathways (16–18).”
BackgroundSelf-citationPolysaccharides regulate Th1/Th2 balance: A new strategy for tumor immunotherapy
Shang, Q., Yu, X., Sun, Q., Li, H., Sun, C., & Liu, L. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115976 · Cited by 156
Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer
Gray, J. E., Saltos, A., Tanvetyanon, T., Haura, E. B., Creelan, B., Antonia, S. J., Shafique, M., Zheng, H., Dai, W., Saller, J. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1305 · Cited by 141
“Finally, inhibitors of enhancer of zeste homologue 2 (EZH2) have also shown an ability to augment expression of Tcell chemokines Cxcl9 and Cxcl10 and enhance response to ICI (17).”
BackgroundChibaya, L., Murphy, K. C., DeMarco, K. D., Gopalan, S., Liu, H., Parikh, C. N., Lopez-Diaz, Y., Faulkner, M., Li, J., Morris, J. P., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00553-8 · Cited by 154
Layer, J. P., Kronmüller, M., Quast, T., Konijnenberg, D., Effern, M., Hinze, D., Althoff, K., Schramm, A. R., Westermann, F., Peifer, M., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1320626 · Cited by 147
“Several studies have shown that the TH1-type chemokine Cxcl10 plays a pivotal role in the recruitment of T cells to the tumor microenvironment enforcing experimental cancer immunotherapies.(34,44) Using a microfluidics-based migration assay, we demonstrated that the conditioned supernatant from N-Myc depleted and DMXA…”
BackgroundKumar, S., Chatterjee, M., Ghosh, P., Ganguly, K. K., Basu, M., & Ghosh, M. K. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.07.024 · Cited by 144
“, inhibition of PI3K-g,(123) CXCL9 and CXCL10) in combination with PD-1/PD-L1 blockade can improve the efficacy and decrease the resistance against this immunotherapy.(124) Metabolic components also play crucial roles in the immunosuppressive TME.”
BackgroundBeyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance
Bell, H. N., & Zou, W. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101819-024752 · Cited by 149
Self-citationRecent updates on cancer immunotherapy
Liu, M., & Guo, F. (2018) · Precision Clinical Medicine · doi:10.1093/pcmedi/pby011 · Cited by 145
Li, J., Yuan, S., Norgard, R. J., Yan, F., Sun, Y. H., Kim, I.-K., Merrell, A. J., Sela, Y., Jiang, Y., Bhanu, N. V., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0519 · Cited by 133
Self-citationHarnessing the chemokine system to home CAR-T cells into solid tumors
Foeng, J., Comerford, I., & McColl, S. R. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100543 · Cited by 165
“Administration of epigenetic modifiers to prevent TH1-type chemokine suppression enhanced intratumoral T cell infiltration, and this effect was abrogated when combined with anti-CXCR3.(15) Furthermore, immunoeditingby IFNgwasdemonstrated to select for tumor variants that had lost CXCL9 expression in MCA-induced fibros…”
BackgroundOverman, M. J., Ernstoff, M. S., & Morse, M. A. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200821 · Cited by 130
Cancer epigenetics: Past, present and future
Lee, J. E., & Kim, M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.025 · Cited by 148
Mechanisms of resistance to immune checkpoint inhibitors
Nagasaki, J., Ishino, T., & Togashi, Y. (2022) · Cancer Science · doi:10.1111/cas.15497 · Cited by 138
The Potential Role of circRNA in Tumor Immunity Regulation and Immunotherapy
Xu, Z., Li, P., Fan, L., & Wu, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00009 · Cited by 136
“Epigenetic silencing of the Th1-type chemokines CXCL9 and CXCL10 through mechanisms such as enhancer of zeste homolog 2 (EZH2)-mediated histone H3 lysine 27 trimethylation and DNA methyltransferase (DNMT) 1-mediated DNA methylation reduces effector T cell trafficking to the tumor microenvironment (31).”
BackgroundEZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells
Kailayangiri, S., Altvater, B., Lesch, S., Balbach, S. T., Göttlich, C., Kühnemundt, J., Mikesch, J., Schelhaas, S., Jamitzky, S., Meltzer, J., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.014 · Cited by 131
Epigenetic regulation in cancer
Gu, M., Ren, B., Fang, Y., Ren, J., Liu, X., Wang, X., Zhou, F., Xiao, R., Luo, X., You, L., et al. (2024) · MedComm · doi:10.1002/mco2.495 · Cited by 138
“227 Therapeutic strategies leveraging this vulnerability, such as the combined use of DNMT and HDAC6 inhibitors, have shown promise, potentiating antitumor immunity by enhancing type I interferon responses and facilitating antigen presentation.”
BackgroundCicchini, L., Westrich, J. A., Xu, T., Vermeer, D. W., Berger, J., Clambey, E. T., Lee, D., Song, J. I., Lambert, P. F., Greer, R. O., et al. (2016) · mBio · doi:10.1128/mbio.00270-16 · Cited by 133
Targeting tumor‑associated macrophages in the tumor microenvironment (Review)
Zhou, K., Cheng, T., Zhan, J., Peng, X., Zhang, Y., Wen, J., Chen, X., & Ying, M. (2020) · Oncology Letters · doi:10.3892/ol.2020.12097 · Cited by 114
“This alteration could be mediated by blocking macrophage infiltration, selectively killing M2‐like TAMs, re‐polarizing M2‐like to M1‐like TAMs or epige‐ netically silencing the secretion of M2‐like TAM‐induced molecules in the TME (44).”
BackgroundOvercoming cold tumors: a combination strategy of immune checkpoint inhibitors
Ouyang, P., Wang, L., Wu, J., Tian, Y., Chen, C., Li, D., Yao, Z., Chen, R., Xiang, G., Gong, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1344272 · Cited by 137
“Enhancer of zeste homologue 2 (EZH2) and DNA methyltransferase 1 (DNMT1) reduce the presence of effector T cells in tumors by inhibiting the production of CXCL9 and CXCL10 by Th1 cells (40).”
BackgroundYuan, W., Lao, X., Xiao, C., Wang, X., Wu, Z.-J., Zeng, Q., Wu, C.-Y., Wu, R., Chen, Z.-X., Zheng, L., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.250 · Cited by 128
E2F7−EZH2 axis regulates PTEN/AKT/mTOR signalling and glioblastoma progression
Yang, R., Wang, M., Zhang, G., Bao, Y., Wu, Y., Li, X., Yang, W., & Cui, H. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01032-y · Cited by 129
Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer
Jones, B. A., Varambally, S., & Arend, R. C. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0437 · Cited by 121
“Lu and colleagues used genomic profiling of endothelial cells from ovarian HGSC and normal ovary to show that EZH2 expression is significantly increased in tumor-associated endothelial cells (30).”
BackgroundMethodInfluentialBhaskaran, V., Nowicki, M. O., Idriss, M., Jimenez, M. A., Lugli, G., Hayes, J. L., Mahmoud, A. B., Zane, R. E., Passaro, C., Ligon, K. L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08390-z · Cited by 105
IL-6 mediates platinum-induced enrichment of ovarian cancer stem cells
Wang, Y., Zong, X., Mitra, S., Mitra, A. K., Matei, D. E., & Nephew, K. P. (2018) · JCI Insight · doi:10.1172/jci.insight.122360 · Cited by 116
“Importantly, epigenetic therapies, especially HMAs, have been demonstrated to reactivate epigenetic silencing in cancer immunotherapy, remove T cell repression, increase effector T cell tumor infiltration, inhibit tumor growth, and improve therapeutic efficacy of immunotherapy, such as anti–PD-1/PD-L1 (51, 52) and NY-…”
BackgroundPD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal Cancer
Chen, L., Xiong, Y., Li, J., Zheng, X., Zhou, Q., Turner, A., Wu, C., Lu, B., & Jiang, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000480000 · Cited by 109
Cancer cell-intrinsic mechanisms driving acquired immune tolerance
Ghorani, E., Swanton, C., & Quezada, S. A. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.004 · Cited by 125
“In primary colon 109 and ovarian cancer cells, 110 PRC2 activity reduced CXCL9 and CXCL10 expression through promoter H3K27 trimethylation.”
BackgroundRecent Advancements in Nanomedicine for ‘Cold’ Tumor Immunotherapy
Chen, Q., Sun, T., & Jiang, C. (2021) · Nano-Micro Letters · doi:10.1007/s40820-021-00622-6 · Cited by 124
Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints
Shi, T., Ma, Y., Yu, L., Jiang, J., Shen, S., Hou, Y., & Wang, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051389 · Cited by 115
“showed that DNMTi 5-aza-2′deoxycytidine (5AZAdC) can up-regulate tumor production of Th1-type chemokines CXCL9 and CXCL10 to increase effector T cell infiltration into TME and improve therapeutic response to PD-L1 blockade compared to PD-L1 blockade alone [52].”
BackgroundZheng, Z., Wieder, T., Mauerer, B., Schäfer, L., Kesselring, R., & Braumüller, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411673 · Cited by 132
“This silencing is negatively associated with the presence of CD8+ T cells in tumors and patient outcomes [241].”
BackgroundTurning cold tumors into hot tumors to ignite immunotherapy
Liu, Y., Wang, Y., Wang, S., Li, J., He, W. A., Fan, X.-J., & Wan, X. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02477-6 · Cited by 135
Tantalo, D. G. M., Oliver, A. J., von Scheidt, B., Harrison, A. J., Mueller, S. N., Kershaw, M. H., & Slaney, C. Y. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002555 · Cited by 122
Fang, F., Cárdenas, H., Huang, H., Jiang, G., Perkins, S. M., Zhang, C., Keer, H. N., Liu, Y., Nephew, K. P., & Matei, D. E. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1492 · Cited by 121
“A recent study using preclinical OC models showed that T helper responses are repressed epigenetically and that removal of this break using epigenetic modulators potentiates response to immunotherapy, including checkpoint inhibitors (47).”
Zhang, J., Zhou, N., Lin, A., Luo, P., Chen, X., Deng, H., Kang, S., Guo, L., Zhu, W., & Zhang, J. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02668-8 · Cited by 125
“Therefore, chemokines (such as CXCL10 and CCL5) and molecules related to cytolytic activity (such as GZMA) that are highly expressed at the mRNA level may be one of the reasons why the efficacy of ICIs is better in ZFHX3-MT patients than in ZFHX3-WT patients.”
BackgroundInfluentialEsfahani, K., Al-Aubodah, T.-A., Thebault, P., Lapointe, R., Hudson, M., Johnson, N. A., Baran, D., Bhulaiga, N., Takano, T., Cailhier, J.-F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12628-1 · Cited by 109
Li, B., Wang, Z., Wu, H., Xue, M., Lin, P., Wang, S., Lin, N., Huang, X., Pan, W., Liu, M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3801 · Cited by 114
Laheurte, C., Dosset, M., Vernerey, D., Boullerot, L., Gaugler, B., Gravelin, E., Kaulek, V., Jacquin, M., Cuche, L., Eberst, G., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0531-5 · Cited by 114
When liposomes met antibodies: Drug delivery and beyond
Di, J., Xie, F., & Xu, Y. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.09.003 · Cited by 107
Rugo, H. S., Jacobs, I. A., Sharma, S., Scappaticci, F. A., Paul, T. A., Jensen-Pergakes, K., & Malouf, G. G. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01379-x · Cited by 113
Zhu, Z., McGray, A. R., Jiang, W., Lu, B., Kaliński, P., & Guo, Z. S. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01664-z · Cited by 115
“The authors suggested that that ATM may serve as both a therapeutic target and a biomarker to enable ICI therapy.”
BackgroundInfluentialEpigenetic modifiers as new immunomodulatory therapies in solid tumours
Aspeslagh, S., Morel, D., Soria, J., & Postel-Vinay, S. C. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy050 · Cited by 105
Adoptive T cell therapy: An overview of obstacles and opportunities
Baruch, E. N., Berg, A. L., Besser, M. J., Schachter, J., & Markel, G. (2017) · Cancer · doi:10.1002/cncr.30491 · Cited by 117
“er, tumors can epigenetically silence T helper 1 cytokine production.(42) This combination of suppressive immune”
BackgroundAdeegbe, D. O., Liu, S., Hattersley, M. M., Bowden, M., Zhou, C. W., Li, S., Vlahos, R., Grondine, M. R., Dolgalev, I., Ivanova, E. V., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0077 · Cited by 110
Racioppi, L., Nelson, E. R., Huang, W., Mukherjee, D., Lawrence, S. A., Lento, W., Masci, A. M., Jiao, Y., Park, S., York, B., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10424-5 · Cited by 104
Therapeutic targeting of DNA methylation alterations in cancer
Lee, A. V., Nestler, K. A., & Chiappinelli, K. B. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108640 · Cited by 124
Ouyang, F., Wu, R., Yuan, W., Liu, R., Yang, D., Xiao, C., Zheng, L., Li, B., Lao, X., & Kuang, D. (2016) · Nature Communications · doi:10.1038/ncomms13453 · Cited by 109
“Thus selectively modulating functional activities of activated stroma cells in patients may provide strategies for anticancer immunotherapies 44–48 .”
Self-citationImmune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets
Stahl, M. F., & Goldberg, A. D. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0781-7 · Cited by 109
Immunotherapy of brain metastases: breaking a “dogma”
Giacomo, A. M. D., Valente, M., Cerase, A., Lofiego, M. F., Piazzini, F., Calabrò, L., Gambale, E., Covre, A., & Maio, M. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1426-2 · Cited by 103
“, MDSC, Treg, chemokines) [37, 38], strongly support the use of epigenetic drugs combined with ICI to develop new strategies for the personalized therapeutic management of patients with brain metastases.”
BackgroundThe epigenetic and transcriptional landscape of neuroendocrine prostate cancer
Davies, A., Zoubeidi, A., & Selth, L. A. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0420 · Cited by 100
“…melanoma and ovarian cancer models, EZH2 is negatively associated with tumour-infiltrating CD8+ T-cells; EZH2-mediated silencing of T-cell attractant chemokines as well as genes essential for antigen processing and presentation represses tumour immunogenicity and T-cell infiltration (Peng et al .”
BackgroundEpigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors
Perrier, A., Didelot, A., Laurent‐Puig, P., Blons, H., & Garinet, S. (2020) · Biomolecules · doi:10.3390/biom10071061 · Cited by 111
“As described previously, EZH2i removes the repression of TH1-type chemokines and increases effector T-cell tumor infiltration, reduces the tumor progression and improves the therapeutic efficacy of anti-PD-L1 [77].”
BackgroundInfluentialThe Cancer Epigenome: Exploiting Its Vulnerabilities for Immunotherapy
Loo Yau, H., Ettayebi, I., & De Carvalho, D. D. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.07.006 · Cited by 96
Chemokine Receptor Signaling and the Hallmarks of Cancer
Lacalle, R. A., Blanco, R., Carmona‐Rodríguez, L., Martín‐Leal, A., Mira, E., & Mañes, S. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.09.011 · Cited by 103
Zhang, W., Liu, W., Jia, L., Chen, D., Chang, I., Lake, M. P., Bentolila, L. A., & Wang, C. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.02.038 · Cited by 105
Sengupta, S., Das, S., Crespo, Â. C., Cornel, A. M., Patel, A. G., Mahadevan, N. R., Campisi, M., Ali, A. K., Sharma, B., Rowe, J. H., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00427-5 · Cited by 106
“Our data also suggest that lineage-restricted immune gene expression is epigenetically regulated, thus adding to the growing body of evidence for tumor cell-autonomous function of PRC2 as a barrier to anti-tumor immunity 59 .”
BackgroundLi, J., Chen, L., Xiong, Y., Zheng, X. W., Xie, Q., Zhou, Q., Shi, L., Wu, C., Jiang, J., & Wang, H. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000460504 · Cited by 99
NSD1 inactivation defines an immune cold, DNA hypomethylated subtype in squamous cell carcinoma
Brennan, K., Shin, J. H., Tay, J. K., Prunello, M., Gentles, A. J., Sunwoo, J. B., & Gevaert, O. (2017) · Scientific Reports · doi:10.1038/s41598-017-17298-x · Cited by 95
“Moreover, PRC2 mediated epigenetic silencing or chemokines, associated with concordant promoter H3K27me3 and DNA hypermethylation, precludes T cell infiltration in ovarian cancer (63).”
Hawila, E., Razon, H., Wildbaum, G., Blattner, C., Sapir, Y., Shaked, Y., Umansky, V., & Karin, N. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.104 · Cited by 98
Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade
Nair, S., Mazzoccoli, L., Jash, A., Govero, J., Bais, S. S., Hu, T., Fontes-Garfias, C. R., Shan, C., Okada, H., Shresta, S., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.144619 · Cited by 96
“Solid tumors with low amounts of T cell infiltration generally do not benefit from immune 290 checkpoint blockade therapy (78-80).”
BackgroundEpigenetic Control of the Tumor Microenvironment
Marks, D. L., Olson, R. L., & Fernandez-Zapico, M. E. (2016) · Epigenomics · doi:10.2217/epi-2016-0110 · Cited by 92
Ramakrishnan, S., Granger, V., Rak, M., Hu, Q., Attwood, K. M., Aquila, L., Krishnan, N., Osiecki, R., Azabdaftari, G., Guru, K. A., et al. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0278-9 · Cited by 102
Miller, N. J., Church, C. D., Dong, L., Crispin, D. A., Fitzgibbon, M., Lachance, K., Jing, L., Shinohara, M. M., Gavvovidis, I., Willimsky, G., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0210 · Cited by 93
“In a mouse model of ovarian cancer, modification of histone methylationwas associatedwith restored secretionof Th-1 cytokines by tumor cells, promoting T-cell infiltration and improved outcomes with T cell–based therapies such as anti–PD-L1 (44).”
BackgroundA New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy
Liu, Z., Ren, Y., Weng, S., Xu, H., Li, L., & Han, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.809761 · Cited by 100
EZH2 regulates PD-L1 expression via HIF-1α in non-small cell lung cancer cells
Zhao, Y., Wang, X., Wu, W., Long, H., Huang, J., Wang, Z., Li, T., Tang, S., Zhu, B., & Chen, D. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.07.039 · Cited by 92
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups, Bedognetti, D., Ceccarelli, M., Galluzzi, L., Lu, R., Palucka, K., Samayoa, J., Spranger, S., Warren, S., Wong, K.-K., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0602-4 · Cited by 88
RNA Modification in the Immune System
Han, D., & Xu, M. M. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101921-045401 · Cited by 97
Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment
Titov, A., Valiullina, A., Zmievskaya, E., Zaikova, E. K., Petukhov, A., Рифкатовна, М. Р., Bulatov, E., & Rizvanov, A. A. (2020) · Cancers · doi:10.3390/cancers12010125 · Cited by 98
The Resistance Mechanisms of Lung Cancer Immunotherapy
Wang, F., Wang, S., & Zhou, Q. H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.568059 · Cited by 98
“(1) DNA methyltransferase inhibitors, e.g., sensitizing tumors to PD-L1 blockade and elevating the secretion of the immunostimulatory chemokines CXCL10 and CXCL9 (155); (2) histone deacetylase inhibitors, as down-regulating MDSCs, increasing the expression of MHC-I and antigen presentation, and increasing tumor-infilt…”
BackgroundInfluentialThe paradigm of drug resistance in cancer: an epigenetic perspective
Adhikari, S., Bhattacharya, A., Adhikary, S., Singh, V., Gadad, S. S., Roy, S., & Das, C. (2022) · Bioscience Reports · doi:10.1042/bsr20211812 · Cited by 96
DNA Methylation: From Cancer Biology to Clinical Perspectives
Chen, C., Wang, Z., Ding, Y., Wang, L., Wang, S., Wang, H., & Qin, Y. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2712326 · Cited by 95
“The application of ICI following combined inhibition of DNMT1 and EZH2 would make ovarian cancer cells to express CXCL9 and CXCL10 , which could activate T helper 1 cells and attract tumor-infiltrating lymphocytes (TILs) [ 147].”
BackgroundInhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation
Zahnow, C. A., Topper, M. J., Stone, M. L., Stewart, T. M., Li, H., Baylin, S. B., & Casero, R. A. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.01.007 · Cited by 95
Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition
Kim, H. J., Cantor, H., & Cosmopoulos, K. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.08.010 · Cited by 92
The role of dendritic cells in cancer
Hansen, M., & Andersen, M. H. (2016) · Seminars in Immunopathology · doi:10.1007/s00281-016-0592-y · Cited by 95
Immune Checkpoint Inhibitors in Cancer Therapy—How to Overcome Drug Resistance?
Lao, Y., Shen, D., Zhang, W., He, R., & Jiang, M. (2022) · Cancers · doi:10.3390/cancers14153575 · Cited by 94
“This can promote the efficacy of PD-L1 inhibitors [173].”
BackgroundPrecision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas
Lue, J. K., Prabhu, S. A., Liu, Y., Gonzalez, Y., Verma, A., Mundi, P. S., Abshiru, N. A., Camarillo, J. M., Mehta, S., Chen, E. I., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3989 · Cited by 95
“During the GC reaction, the PRC2 complex recruits histone deacetyltransferase (HDAC) 1/2 and DNA methyltransferases (DNMT) to further inhibit transcription (2, 3).”
BackgroundInfluentialWang, H., Li, S., Wang, Q., Jin, Z., Shao, W., Gao, Y., Li, L., Lin, K., Zhu, L., Wang, H., et al. (2021) · Science Advances · doi:10.1126/sciadv.abd7851 · Cited by 93
Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy
Yuan, Y. J., Adam, A., Zhao, C., & Chen, H. (2021) · Cancers · doi:10.3390/cancers13040663 · Cited by 92
“Research reveals that epigenetic silencing of CXCL9 and CXCL10 can suppresses T-cell homing [123].”
BackgroundWang, B., Yin, H., Zhang, Y., Zhao, Q., Wang, H., Wei, J., Meng, L., Xin, Y., & Jiang, X. M. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01073-9 · Cited by 92
“[83] revealed that cancer epigenetic silencing consisting of enhancer of zeste homolog 2 (EZH2)-mediated histone modifications and DNA methyltransferase (DNMT) -mediated DNA methylation of the gene encoding the T helper 1-type chemokines, CXCL9 and CXCL10, decreased T cells homing and infiltration, thus potentially im…”
BackgroundWolff, F., Leisch, M., Greil, R., Risch, A., & Pleyer, L. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-017-0168-z · Cited by 89
“3) Treatment with AZA nucleosides causes demethylation of the hypermethylated CpG islands in MDS/AML leading to reactivation of tumor suppressor genes and anti-leukemic effects This reduced and triphosphorylated form of AZA is incorporated into genomic DNA and covalently traps DNMT1 at DAC-guanine dinucleotides at the…”
BackgroundInfluentialZheng, Y., Wang, Z., Wei, S., Liu, Z., & Chen, G. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.034 · Cited by 88
Self-citationKallert, S. M., Darbre, S., Bonilla, W. V., Kreutzfeldt, M., Page, N., Müller, P., Kreuzaler, M., Lu, M., Favre, S., Kreppel, F., et al. (2017) · Nature Communications · doi:10.1038/ncomms15327 · Cited by 88
DNA Methyltransferase Inhibitors: Catalysts For Antitumour Immune Responses
Dan, H., Zhang, S., Zhou, Y., & Guan, Q. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s217767 · Cited by 86
“DNA methyltransferase 1 (DNMT1)-mediated DNAmethylation inhibits tumour production of the T helper 1 (TH1)-type chemokines CXCL9 and CXCL10, which in turn affect the transport of effector T cells to the tumour microenvironment.(82) These processes further define the pathway by which epigenetic therapy may remodel the…”
BackgroundKRT17 Promotes T-lymphocyte Infiltration Through the YTHDF2–CXCL10 Axis in Colorectal Cancer
Liang, W., Liu, H., Zeng, Z., Liang, Z., Xie, H., Li, W., Xiong, L., Liu, Z., Chen, M., Jie, H., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0814 · Cited by 90
“It has been shown that the histone modulator EZH2 modulates the transcription of the chemokines CXCL9 and CXCL10 by regulating DNMT1-mediated DNA methylation to prevent T-cell migration into tumors (46, 47).”
Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
Xiao, Q., Nobre, A., Piñeiro, P., Berciano‐Guerrero, M., Alba, E., Cobo, M., Lauschke, V. M., & Barragán, I. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010286 · Cited by 83
Sun, S., Feng, Y., Xu, D., Zheng, H., & Li, M. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188700 · Cited by 87
Wang, Y., Lei, Y., Hu, Z.-L., Fang, Y.-F., Shen, Y., Song, M., & Chen, Y. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05169-x · Cited by 88
“Consistently, other study reports that EZH2-mediated H3K27me3 and DNMT1-mediated DNA methylation inhibit the expression of tumor-derived T helper 1 (TH1)-type chemokines CXCL9 and CXCL10, and treatment with epigenetic modulators gets rid of the suppression, promotes tumor-infiltrating effector T-cells and strengthens…”
BackgroundRegulation of T Cell Differentiation and Function by EZH2
Karantanos, T., Chistofides, A., Barhdan, K., Li, L., & Boussiotis, V. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00172 · Cited by 81
“…cells by inhibition of EZH2 and DNA methyltransferase 1 (DNMT1) in a mouse model of ovarian cancer resulted in increased expression of the Th1-type chemokines CXCL9 and CXCL10 in cancer cells leading to increased trafficking of effector T cells to the tumor site and decreased tumor volume (36).”
BackgroundInfluences of the Gut Microbiota on DNA Methylation and Histone Modification
Ye, J., Wu, W., Li, Y., & Li, L. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4538-6 · Cited by 84
Li, C., Wang, Y., Gong, Y., Zhang, T., Huang, J., Tan, Z. W., & Xue, L. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01045-1 · Cited by 84
“Moreover, EZH2 expression in tumors is negatively associated with the population of tumor-infiltrating CD8+ T cells and patient outcome, thus providing a rationale for the combination of EZH2i and adoptive T cell transfer therapy [45].”
BackgroundThe evolutionary legacy of immune checkpoint inhibitors
Kaushik, I., Ramachandran, S., Zabel, C., Gaikwad, S., & Srivastava, S. K. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.020 · Cited by 79
Epigenetics in modulating immune functions of stromal and immune cells in the tumor microenvironment
Pan, X., & Zheng, L. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0505-9 · Cited by 75
“, linked effector T-cell differentiation with both DNA methylation and histone methylation in human ovarian cancer.(121) The authors discovered that EZH2mediated histone H3 lysine 27 trimethylation (H3K27me3) and DNA methyltransferase 1 (DNMT1)-mediated DNA methylation Fig.”
BackgroundEZH2 Inhibition: A Promising Strategy to Prevent Cancer Immune Editing
Kang, N., Eccleston, M., Clermont, P., Latarani, M., Male, D. K., Wang, Y. Z., & Crea, F. (2020) · Epigenomics · doi:10.2217/epi-2020-0186 · Cited by 83
Epigenetic strategies to boost CAR T cell therapy
Akbari, B., Ghahri-Saremi, N., Soltantoyeh, T., Hadjati, J., Ghassemi, S., & Mirzaei, H. R. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.08.003 · Cited by 82
Multifaceted role of chemokines in solid tumors: From biology to therapy
Raza, S., Rajak, S., Tewari, A., Gupta, P., Chattopadhyay, N., Sinha, R. A., & Chakravarti, B. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.12.011 · Cited by 85
DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma
Zhang, L., Li, H., Shereda, R., Lu, Q., Weisenberger, D. J., O'Connell, C. L., Machida, K., An, W., Lenz, H., El-Khoueiry, A. B., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215899 · Cited by 84
Wang, Y., Chen, J., Chang, C.-W., Jen, J., Huang, T.-Y., Chen, C., Shen, R., Liang, S., Cheng, I., Yang, S., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89957 · Cited by 87
“On one hand, activation of tumor-intrinsic oncogenes such as β -caten- in ( CTNNB1 ) (51), STAT3 (52, 53), enhancer of zeste 2 polycomb– repressive complex 2 subunit ( EZH2 ), and DNA methyltransferase 1 ( DNMT1 ) (54) and loss of function of the tumor suppressor p53 (55) have been shown to contribute to immune exclus…”
Huang, Q., Ma, C., Chen, L., Luo, D., Chen, R., & Liang, F. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00370 · Cited by 78
“These changes interfere with metabolic homeostasis and result in body adiposity (21, 22).”
BackgroundEpigenetic modulation enhances immunotherapy for hepatocellular carcinoma
Hong, Y. K., Li, Y., Pandit, H., Li, S., Pulliam, Z., Zheng, Q., Yu, Y., & Martin, R. C. G. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2018.12.010 · Cited by 81
Metadata
- Authors
- Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., Kotarski, J., Tarkowski, R., Dou, Y., Cho, K., Hensley-Alford, S., Munkarah, A., Liu, R., & Zou, W.
- Affiliations
- University of Michigan (US)
- Medical University of Lublin (PL)
- Henry Ford Health (US)
- Corresponding author
- Zou, Weiping
- ORCID
- Venue
- Nature
- Published
- 2015-10-26
- Volume
- 527
- Issue
- 7577
- Pages
- 249-253
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4779053
- OpenAlex
- W2103021272
- Cited by
- 1,201
- References
- 37
- Citations by year
- 2026: 79 · 2025: 100 · 2024: 104 · 2023: 132 · 2022: 155 · 2021: 159 · 2020: 125 · 2019: 109 · 2018: 85 · 2017: 89 · 2016: 61 · 2015: 2
- FWCI
- 34.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (CA099985, R01CA123088, R01CA152470, CA193136, R01CA156685, CA123088, 5P30 CA 46592, CA156685, CA152470, R01CA171306, R01CA193136, CA171306, R01CA099985, F31CA189440, R01CA190176, CA190176, P30CA046592)
- National Institute of General Medical Sciences (R01GM082856)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- epigenetic silencing, EZH2, DNMT1, CXCL9, CXCL10, ovarian cancer, tumor immunosuppression, adoptive T cell therapy, CD8+ T cells, H3K27me3, DNA methylation, histone modifications, tumor microenvironment, immunotherapy response
- MeSH terms
- Enhancer of Zeste Homolog 2 Protein, DNA (Cytosine-5-)-Methyltransferase 1, Animals, DNA (Cytosine-5-)-Methyltransferases, Female, Histones, Humans, Immunotherapy, Lysine, Ovarian Neoplasms, Prognosis, Tumor Cells, Cultured, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Th1 Cells, Chemokines, Tumor Escape, DNA Methylation, Gene Silencing, Xenograft Model Antitumor Assays, Epigenesis, Genetic, Mice, Chemokine CXCL10, Chemokine CXCL9, B7-H1 Antigen, Polycomb Repressive Complex 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.